Exelixis (EXEL) Competitors

Exelixis (NASDAQ:EXEL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk.

Does the MarketBeat Community favor EXEL or ALNY?

Alnylam Pharmaceuticals received 543 more outperform votes than Exelixis when rated by MarketBeat users. Likewise, 76.31% of users gave Alnylam Pharmaceuticals an outperform vote while only 68.58% of users gave Exelixis an outperform vote.

Company	Underperform	Outperform
Exelixis	Outperform Votes 620 68.58%	Underperform Votes 284 31.42%
Alnylam Pharmaceuticals	Outperform Votes 1163 76.31%	Underperform Votes 361 23.69%

Do analysts prefer EXEL or ALNY?

Exelixis presently has a consensus price target of $37.59, indicating a potential upside of 3.41%. Alnylam Pharmaceuticals has a consensus price target of $315.58, indicating a potential upside of 36.56%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	8 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alnylam Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.77

Does the media prefer EXEL or ALNY?

In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than Exelixis. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 22 mentions for Exelixis. Exelixis' average media sentiment score of 1.36 beat Alnylam Pharmaceuticals' score of 0.84 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	19 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals have more ownership in EXEL or ALNY?

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 2.9% of Exelixis shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has more volatility and risk, EXEL or ALNY?

Exelixis has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Which has preferable valuation and earnings, EXEL or ALNY?

Exelixis has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.17B	4.69	$521.27M	$1.77	20.54
Alnylam Pharmaceuticals	$2.25B	13.37	-$278.16M	-$2.17	-106.50

Is EXEL or ALNY more profitable?

Exelixis has a net margin of 24.04% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Exelixis' return on equity of 23.52% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	24.04%	23.52%	17.95%
Alnylam Pharmaceuticals	-12.37%	N/A	-6.83%

Summary

Exelixis and Alnylam Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.